Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors

NCT03134638 is registered in ClinicalTrials.gov with Syros Pharmaceuticals as lead sponsor.

NCT NCT03134638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03134638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
Lead sponsor
Syros Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
May 12, 2017
Completion date
June 24, 2020
Enrollment
107 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, breast cancer, ovarian cancer